Physician profile
Samir Elian
NPI 1548235369
$11,428.03
in general payments reported to CMS, 2019-2025
41 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $2,999 · 2021: $914 · 2022: $1,309 · 2023: $1,909 · 2024: $1,561 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236 · Travel and Lodging: $614 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.03 |
| Travel and Lodging | $613.61 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,618.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,444.74 | 2019-2025 | |
| Boston Scientific Corporation | $1,006.73 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Resonate El Icd Vr |
| Merck Sharp & Dohme LLC | $859.72 | 2021-2025 | Verquvo, Capvaxive, Lagevrio |
| Philips North America LLC | $740.36 | 2025 | Igt Devices Undivided, Event |
| Amgen INC. | $554.18 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $389.45 | 2021-2023 | Opsumit, Uptravi |
| Pfizer INC. | $281.35 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.84 | 2020-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $233.18 | 2021-2024 | Xarelto |
| Biotronik INC. | $232.00 | 2020-2023 | Acticor 7 Vr-T Dx |
| Alnylam Pharmaceuticals INC. | $160.68 | 2023-2025 | Onpattro |
| Cook Medical LLC | $144.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.40 | 2020-2022 | |
| Esperion Therapeutics, INC. | $141.11 | 2020-2023 | Nexletol |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $135.98 | 2021-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $124.74 | 2023 | |
| Kestra Medical Technology Services, INC. | $119.50 | 2022-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $103.23 | 2021-2023 | Arcalyst |
| Cordis US Corp. | $82.27 | 2021-2024 | Mynxgrip, Infiniti |
| Getinge USA Sales, LLC | $72.96 | 2021-2022 | |
| Novo Nordisk INC | $65.34 | 2024 | Rybelsus, Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $63.03 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $59.22 | 2023-2024 | |
| Inari Medical, INC. | $51.04 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Vital Connect, INC | $35.98 | 2024 | Vitalpatch Rtm |
| Medtronic, INC. | $34.98 | 2021-2022 | |
| Vivaquant INC, Dba Rhythm Express | $29.25 | 2024-2025 | Rhythm Express, Rhythm Express |
| Baxter Healthcare | $29.09 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $23.81 | 2022 | |
| Daiichi Sankyo INC. | $23.10 | 2024 | Injectafer |
| Cardinal Health 200 LLC | $21.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.94 | 2024 | Jardiance |
| Cardiovascular Systems INC. | $20.62 | 2021 | |
| Astellas Pharma US INC | $20.57 | 2019 | |
| Heartflow, INC. | $19.74 | 2025 | |
| Abbott Laboratories | $18.21 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.79 | 2024 | |
| Abiomed | $17.14 | 2023 | Impella |
| Bridgebio Pharma, INC. | $14.74 | 2025 | Attruby |
| Bardy Diagnostics, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Elian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.